• Cat-intel
  • MedIntelliX
  • Consulting
  • Resources
  • About Us
  • News
  • Careers
  • Contact Us
  • Login

    • Renal Disease Companies

    ID: MRFR/Pharma/2289-CR
    157 Pages
    Kinjoll Dey
    February 2021

    Renal disease, often referred to as kidney disease, encompasses various medical conditions that affect the kidneys' structure and function. It includes conditions such as chronic kidney disease (CKD), acute kidney injury (AKI), kidney stones, and polycystic kidney disease, among others. Numerous companies are involved in the development of diagnostic tools, medical devices, pharmaceuticals, and treatment options for renal diseases.

    Share:
    Download PDF ×

    We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

    Renal Disease Market Research Report - Forecast till 2032 Infographic
    Summary Table of Contents Segmentation Infographic

    Top Industry Leaders in the Renal Disease Market

    Renal Disease Key CompaniesDisclaimer: List of key companies in no particular orderLatest Renal disease Companies Update



    • October 2023: In order to better serve patients with anemia caused by kidney disease, Zydus Lifesciences Limited and Sun Pharmaceutical Industries Limited (Sun Pharma) have signed a licensing agreement to co-market a new medication. According to the drug's creators, Desidustat is the first oral medication of its sort in India to treat anemia caused by CKD. In accordance with the terms of the agreement, Zydus has licensed the RYTSTAT brand to Sun Pharma for semi-exclusive comarketing in India. Oxemia, the drug's brand name, was introduced by Zydus in 2022, and the company plans to keep selling it. Zydus will get license fees up front and additional money for reaching objectives.




    • October 2023: Novartis revealed favorable topline data from the interim analysis of the ongoing pivotal Phase III ALIGN trial of atrasentan, an oral endothelin A receptor antagonist (ERA), in patients with IgAN. The safety profile of atrasentan in the trial matched that seen in the Phase II AFFINITY study's IgAN cohort, which had previously been reported. Novartis expects to submit an application in 2024 for potential expedited approval in the US based on the results of this interim proteinuria endpoint study. With clinically substantial proteinuria decrease, these promising topline Phase III findings highlight the potential of atrasentan to enhance outcomes for patients with IgAN. Their development portfolio of three highly differentiated late-stage therapies in IgAN has the potential to provide much-needed treatment options for people living with this debilitating disease, including iptacopan, which recently also showed positive topline Phase III results.


    List of Renal disease Key companies in the market

    • Abbott (US)

    • Amgen Inc. (US)

    • AstraZeneca (UK)

    • Bristol-Myers Squibb Company (US)

    • Hoffmann-La Roche Ltd. (Switzerland)

    • Pfizer Inc. (US)

    • GlaxoSmithKline PLC (UK)

    • Keryx Biopharmaceuticals, Inc. (US)

    • Kissei Pharmaceutical Co., Ltd. (Japan)

    • Novartis (Switzerland)